Efficacy and safety of dapagliflozin combined with insulin in overweight or obese individuals with type 2 diabetes.

To investigate the efficacy and safety of dapagliflozin plus insulin in overweight or obese individuals with type 2 diabetes, from January to June 2019, 85 patients with type 2 diabetes were treated at Harrison International Peace Hospital and were randomized to either a combination group (43 cases) or a control group (42 cases). The control group received insulin, whereas the combination group additionally received dapagliflozin. On the first, second, fifth and tenth days, insulin doses and the time taken for standardized blood glucose were documented and their effectiveness and safety were compared. The time taken for standard insulin in the combination group was shorter vs. control group [(4.32±0.41) d vs. (6.93±0.57) d] and the difference in the dosage of insulin statistically significant (all P<0.05); there were significant differences in fasting blood glucose (FPG), 2h postprandial blood glucose (2hPBG) and hemoglobin a1c (HbA1c), fasting serum insulin (FINS) and homeostatic model assessment of beta (HOMA-β) between the two groups and within the two groups (all P<0.05); the incidence of adverse reactions was lower in the combination grou [4.65% (2/43) vs. 11.90% (6/42)] (P<0.05). Dapagliflozin plus insulin improves blood glucose and islet β cell activity with a good safety profile in overweight or obese individuals with type 2 diabetes.